With the global pandemic firmly in the rearview mirror, life sciences companies are looking at key macro- and micro- economic drivers to guide their future growth. While the list of trends with wide-ranging global impact is broad, in this year, life sciences enterprises are paying particular attention to those more disruptive trends including increasing pricing pressures and changes in United States regulation, the acceleration of Generative AI (GenAI) adoption and impact, the geo-political environment, and as always, breakthrough science and outcomes. Companies are exploring how the evolution of GenAI can impact their operations and determining where to focus first and how to generate differential value. The potential of advanced technologies and these collaborations are directly integrated with life sciences companies’ overall efforts to improve patient outcomes and inform their R&D decisions.